Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 20, 2009
Resistance mechanisms of tumour cells to EGFR inhibitorsF Morgillo, F Cantile, M Fasano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2007
Erlotinib in cancer treatmentM A Bareschino, C Schettino, T Troiani, et al.
Cancer Treatment Reviews|June 30, 2018
It is finally time for adjuvant therapy in melanomaS Napolitano, G Brancaccio, G Argenziano, et al.
Current Medicinal Chemistry|September 3, 2013
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancerT Troiani, E Martinelli, S Napolitano, et al.
Current Drug Targets|March 31, 2012
Targeting EGFR in pancreatic cancer treatmentT Troiani, E Martinelli, A Capasso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2006
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapyF Ciardiello, T Troiani, R Bianco, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|July 19, 2011
Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trialsM Orditura, G Galizia, F Morgillo, et al.
British Journal of Cancer|July 14, 2011
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitorsF Morgillo, T Cascone, E D'Aiuto, et al.
European Review for Medical and Pharmacological Sciences|July 6, 2021
Inherited predisposition to malignant mesothelioma: germline BAP1 mutations and beyondF Pagliuca, F Zito Marino, F Morgillo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2011
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II studyC Gridelli, F Morgillo, A Favaretto, et al.
Pageof 3